Practical insights on market access: How viable are ATMPs from an EU payer perspective?

11 Sep 2018

09:30 - 10:15

Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement

Practical methods for reimbursement in a multinational network
How are EU payers and HTA bodies viewing these therapies from a pricing perspective? Is the clinical effectiveness of CAR-T and other ATMPs justifying the cost of treatment?
How will we fairly price single dose curative therapies?
Can we build a new way to fund, assess and pay for these treatments together?

Speakers

Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities

Jean-Philippe Combal
GenSight Biologics
The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.

Michael Covington
Juno Therapeutics, Inc
It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance

Bertrand Alexandre
Celyad
Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.

Dr Ohad Karnieli
Karnieli Ltd

Phacilitate Leaders Europe Agenda 2018